RPRX•globenewswire•
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
Summary
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 4, 2025 by globenewswire